India's Zydus joins fight against novel coronavirus

Ahmedabad, India-based Zydus Cadila, a part of Cadila Healthcare (NSE: CADILAHC), has launched an accelerated research program to develop a vaccine for the novel coronavirus, COVID-19.

The Indian drugmaker says it will launch a two-pronged approach, with a team at the Vaccine Technology Center in India and another at the firm’s research arm in Europe, Etna Biotech, working on the project.

The first approach is centered around the development of a DNA vaccine against the major viral membrane protein which is responsible for the cell entry of the novel coronavirus.